Logo image of BCAX

BICARA THERAPEUTICS INC (BCAX) Stock Fundamental Analysis

NASDAQ:BCAX - Nasdaq - US0554771032 - Currency: USD

16.55  +0.8 (+5.08%)

After market: 16.55 0 (0%)

Fundamental Rating

3

Overall BCAX gets a fundamental rating of 3 out of 10. We evaluated BCAX against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BCAX as it has an excellent financial health rating, but there are worries on the profitability. BCAX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BCAX had negative earnings in the past year.
BCAX Yearly Net Income VS EBIT VS OCF VS FCFBCAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of BCAX (-9.92%) is better than 87.09% of its industry peers.
Looking at the Return On Equity, with a value of -10.20%, BCAX belongs to the top of the industry, outperforming 90.23% of the companies in the same industry.
Industry RankSector Rank
ROA -9.92%
ROE -10.2%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCAX Yearly ROA, ROE, ROICBCAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 0 200 -200 -400

1.3 Margins

BCAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCAX Yearly Profit, Operating, Gross MarginsBCAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023

More info and screens

9

2. Health

2.1 Basic Checks

BCAX has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for BCAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCAX Yearly Shares OutstandingBCAX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 10M 20M 30M 40M 50M
BCAX Yearly Total Debt VS Total AssetsBCAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 50M 100M 150M 200M

2.2 Solvency

BCAX has an Altman-Z score of 37.34. This indicates that BCAX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BCAX (37.34) is better than 97.38% of its industry peers.
BCAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 37.34
ROIC/WACCN/A
WACCN/A
BCAX Yearly LT Debt VS Equity VS FCFBCAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 36.01 indicates that BCAX has no problem at all paying its short term obligations.
BCAX has a better Current ratio (36.01) than 98.43% of its industry peers.
A Quick Ratio of 36.01 indicates that BCAX has no problem at all paying its short term obligations.
The Quick ratio of BCAX (36.01) is better than 98.43% of its industry peers.
Industry RankSector Rank
Current Ratio 36.01
Quick Ratio 36.01
BCAX Yearly Current Assets VS Current LiabilitesBCAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

BCAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.35%.
EPS 1Y (TTM)-37.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -31.12% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-164.18%
EPS Next 2Y-32.18%
EPS Next 3Y-31.12%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCAX Yearly Revenue VS EstimatesBCAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026
BCAX Yearly EPS VS EstimatesBCAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BCAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCAX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCAX Price Earnings VS Forward Price EarningsBCAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCAX Per share dataBCAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as BCAX's earnings are expected to decrease with -31.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-32.18%
EPS Next 3Y-31.12%

More info and screens

0

5. Dividend

5.1 Amount

BCAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BICARA THERAPEUTICS INC

NASDAQ:BCAX (3/7/2025, 8:06:53 PM)

After market: 16.55 0 (0%)

16.55

+0.8 (+5.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners79.96%
Inst Owner Change29.77%
Ins Owners0.16%
Ins Owner Change0%
Market Cap900.65M
Analysts85
Price Target40.55 (145.02%)
Short Float %8.73%
Short Ratio9.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.84%
PT rev (3m)-4.22%
EPS NQ rev (1m)1.49%
EPS NQ rev (3m)1.39%
EPS NY rev (1m)-0.04%
EPS NY rev (3m)8.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.77
P/tB 1.77
EV/EBITDA N/A
EPS(TTM)-1
EYN/A
EPS(NY)-1.75
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS9.36
TBVpS9.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.92%
ROE -10.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 36.01
Quick Ratio 36.01
Altman-Z 37.34
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-164.18%
EPS Next 2Y-32.18%
EPS Next 3Y-31.12%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-91.94%
EBIT Next 3Y-48.62%
EBIT Next 5YN/A
FCF growth 1Y-43.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.25%
OCF growth 3YN/A
OCF growth 5YN/A